Newsletter Tool

Featured Story

Novartis CEO: Leqvio, Pluvicto off to solid starts, but blockbuster sales will take time

By Angus Liu

Novartis has high hopes for newly launched heart drug Leqvio and cancer therapy Pluvicto. To hear CEO Vas Narasimhan tell it, both products are off to a strong start in their multiyear journeys to more than $2 billion in sales each.

After a down first quarter, investors question why UHS isn't adjusting its 2022 guidance

By Dave Muoio

An ongoing workforce shortage challenged UHS' acute care hospitals and, to a greater extent, its behavioral care facilities, leading the system to miss its internal Q1 earnings goal by 6%.

Abiomed implants first patient with long-term, removable heart pump

By Conor Hale

Abiomed has treated its first patient with its minimally invasive heart pump designed to serve as a “bridge-to-recovery” for people suffering from severe heart failure.

After Biohaven stopped teasing Nurtec's quarterly performance, should investors be worried?

By Angus Liu

Biohaven Pharmaceuticals has been offering early peeks at the performance of its closely watched migraine drug launch since the fourth quarter of 2020. So, when the company recently stopped the practice of issuing preliminary results, investors started to worry.

Editas sees clinical promise with new FDA pediatric disease tag for another blood disorder

By Gabrielle Masson

Amid chaos comes good news—Editas Medicine has received rare pediatric disease designation from the FDA for its gene-edited medicine EDIT-301 to treat beta thalassemia.

Centene unveils refresh of its Office of the CEO

By Paige Minemyer

Centene posted $849 million in profit for the first quarter, up 21% year over year. Revenue leapt even more—by 24%—in CEO Sarah London's first earnings report on the job.

After phase 2 flop, BerGenBio posts new data on COVID-19 prospect

By Nick Paul Taylor

The effort to establish bemcentinib as a COVID-19 drug continues. Eleven months after failing a phase 2 trial, the Danish biotech has shared data from a second, smaller trial that linked the drug to significant changes.

Lawmakers ask FDA to lay out plans for reviewing COVID vaccines for young children

By Zoey Becker

Congress's COVID-19 committee is requesting a scientific explanation for a perceived delay by the FDA in reviewing Moderna's mRNA vaccine in young children.

Biofourmis banks $300M megaround to fuel its growth in remote care, potential M&A deals

By Heather Landi

Three years ago, technology startup Biofourmis raised $10 million in total funding to build out its virtual care and digital therapeutics business. This week, the virtual care and digital medicine-focused company announced a massive $300 million cash injection to fuel its growth.

Pfizer-Valneva's Lyme disease vaccine performs even better in children

By Annalee Armstrong

Pfizer and Valneva’s Lyme disease vaccine worked even better in children than adults, leading the partners to add this population to a late-stage test beginning in the third quarter.

PM Tracker